COVID-19 pneumonia. COVID-19, virus not identified
Conditions
Interventions
Intervention 1: Intervention group: Participants receive Hydroxychloroquine (Amin Pharmaceutical company, Isfahan) at dose of 200 mg TDS up to 7 days. Intervention 2: Control group: Participants rece
Sponsors
Shahid Beheshti University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Age over 18 years old Close contact with COVID-19 patient at least in past 4 days sign the informed consent form to participate in study
Exclusion criteria
Exclusion criteria: Pervious case of COVID-19 Current case of COVID-19 Presenting influenza like symptoms (fever, cough, and sore throat) in last 30 days Travel history in last 14 days Lactation and pregnancy History of arrhythmia Drug allergy history Favism history Chronic liver disease Chronic kidney disease Retinopathy history Weight under 40 kg Patients who are receiving arritmogenica medicines
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Disease severity. Timepoint: At end of the study. Method of measurement: Clinical scoring for disease severity.;Death. Timepoint: Day 7, day 14, and day 28. Method of measurement: Observation.;Adverse reactions. Timepoint: Daily. Method of measurement: Observation. | — |
Primary
| Measure | Time frame |
|---|---|
| Fever. Timepoint: Daily. Method of measurement: Thermometer.;Cough. Timepoint: Daily. Method of measurement: Questionnaire.;Dyspnea. Timepoint: Daily. Method of measurement: Questionnaire.;Sore throat. Timepoint: Daily. Method of measurement: Questionnaire.;Myalgia. Timepoint: Daily. Method of measurement: Questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactOmidvar Rezaiemirghaed
Shahid Beheshti University of Medical Sciences
Outcome results
None listed